OJEMDA 25 mg/ml susp 300 mg 1 pce

7680702410012 CH-70241 L01EC04 07.16.1.

No images available

Details

Product number
7024101
CPT
-
Packaging group
1
Unit
Flasche(n)
Composition
tovorafenibum 300 mg, copovidonum, cellulosum microcristallinum, mannitolum, natrii laurilsulfas corresp. natrium 2.5 mg, simeticonum, maltodextrinum, silica colloidalis anhydrica, sucralosum, aromatica (Erdbeere), ad pulverem corresp. suspensio reconstituta 12 ml.

Articles (1)

Ojemda 25 mg/ml, Pulver zur Herstellung einer Suspension zum Einnehmen
Pulver zur Herstellung einer Suspension zum Einnehmen
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
13/06/2026
Patient information leaflet
Français
13/06/2026
Patient information leaflet
Italien
13/06/2026
Professional SmPC
Allemand
13/06/2026
Professional SmPC
Français
13/06/2026
Professional SmPC
Italien
13/06/2026

Detailed composition

Substance Quantity Type Category
tovorafenibum
300.0 MG Substance Wirkstoff (Principe actif)
copovidonum
- Substance HNIDK
cellulosum microcristallinum
- Substance HNIDK
mannitolum
- Substance HNIDK
natrii laurilsulfas
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
natrium
2.5 MG Substance HBESI
simeticonum
- Substance HNIDK
maltodextrinum
- Substance HNIDK
silica colloidalis anhydrica
- Substance HNIDK
sucralosum
- Substance HNIDK
aromatica
- Substance AROMA

Authorization holder

IPSEN Pharma Schweiz GmbH

6300 Zug

Authorization information

Swissmedic authorization number
70241
Drug name
Ojemda, Pulver zur Herstellung einer Suspension zum Einnehmen
Galenic form
PULS
ATC Code
L01EC04
Authorization status
B
Dispensation category
A
First authorization
05/05/2026
Authorization expiration date
05/05/2028
IT number
07.16.1.
Domain
Human medicine
Field of application
Pädiatrisches niedriggradiges Gliom mit BRAF‑Fusion, ‑Rearrangement oder BRAF‑V600‑Mutation nach vorangegangener systemischer Therapie.

Packaging details

Description (FR)
OJEMDA 25 mg/ml susp 300 mg 1 pce
Description (DE)
OJEMDA 25 mg/ml Susp 300 mg 1 Stk
Market launch
01/07/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data